Trial Outcomes & Findings for Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications (NCT NCT00809146)
NCT ID: NCT00809146
Last Updated: 2016-06-17
Results Overview
The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.
COMPLETED
PHASE3
1023 participants
Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).
2016-06-17
Participant Flow
Subjects treated for status epilepticus in the prehospital setting by paramedics were enrolled at the scene between June 2009 and January 2011. A total of 1023 subject enrollments represented 893 unique subjects with a reenrollment rate of 13%. RAMPART involved 4314 paramedics, 33 EMS agencies, and 79 receiving hospitals across the United States.
Number of patients enrolled includes any repeat enrollments for those who presented to emergency medical services (EMS) with status epilepticus more than once. The number assigned to treatment in the intention-to-treat analysis includes every patient who was enrolled in the study but only the initial enrollment for those enrolled more than once.
Participant milestones
| Measure |
Intramuscular (IM) Anticonvulsant
This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
|
Intravenous (IV) Anticonvulsant
This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
|
|---|---|---|
|
Overall Study
STARTED
|
448
|
445
|
|
Overall Study
COMPLETED
|
448
|
445
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications
Baseline characteristics by cohort
| Measure |
Intramuscular (IM) Anticonvulsant
n=448 Participants
This group gets active treatment with an anticonvulsant by the intramuscular route of administration. IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
|
Intravenous (IV) Anticonvulsant
n=445 Participants
This group gets active treatment with an anticonvulsant by the intravenous route of administration. IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
|
Total
n=893 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
43 years
STANDARD_DEVIATION 22 • n=99 Participants
|
44 years
STANDARD_DEVIATION 22 • n=107 Participants
|
43 years
STANDARD_DEVIATION 22 • n=206 Participants
|
|
Age, Customized
0-5 years
|
32 participants
n=99 Participants
|
29 participants
n=107 Participants
|
61 participants
n=206 Participants
|
|
Age, Customized
6-10 years
|
15 participants
n=99 Participants
|
20 participants
n=107 Participants
|
35 participants
n=206 Participants
|
|
Age, Customized
11-20 years
|
28 participants
n=99 Participants
|
21 participants
n=107 Participants
|
49 participants
n=206 Participants
|
|
Age, Customized
21-40 years
|
114 participants
n=99 Participants
|
112 participants
n=107 Participants
|
226 participants
n=206 Participants
|
|
Age, Customized
41-60 years
|
169 participants
n=99 Participants
|
169 participants
n=107 Participants
|
338 participants
n=206 Participants
|
|
Age, Customized
>61 years
|
90 participants
n=99 Participants
|
94 participants
n=107 Participants
|
184 participants
n=206 Participants
|
|
Sex: Female, Male
Female
|
198 Participants
n=99 Participants
|
207 Participants
n=107 Participants
|
405 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
250 Participants
n=99 Participants
|
238 Participants
n=107 Participants
|
488 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
49 Participants
n=99 Participants
|
57 Participants
n=107 Participants
|
106 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
310 Participants
n=99 Participants
|
290 Participants
n=107 Participants
|
600 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
89 Participants
n=99 Participants
|
98 Participants
n=107 Participants
|
187 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
3 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
8 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
2 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
229 Participants
n=99 Participants
|
224 Participants
n=107 Participants
|
453 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
165 Participants
n=99 Participants
|
183 Participants
n=107 Participants
|
348 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
9 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
14 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
32 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
45 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
448 participants
n=99 Participants
|
445 participants
n=107 Participants
|
893 participants
n=206 Participants
|
|
Dose tier
children with an estimated weight of 13 to 40 kg
|
62 participants
n=99 Participants
|
59 participants
n=107 Participants
|
121 participants
n=206 Participants
|
|
Dose tier
Children estimated >40kg and All Adults
|
386 participants
n=99 Participants
|
386 participants
n=107 Participants
|
772 participants
n=206 Participants
|
|
History of epilepsy
Yes
|
293 participants
n=99 Participants
|
295 participants
n=107 Participants
|
588 participants
n=206 Participants
|
|
History of epilepsy
No
|
111 participants
n=99 Participants
|
103 participants
n=107 Participants
|
214 participants
n=206 Participants
|
|
History of epilepsy
Not documented
|
44 participants
n=99 Participants
|
47 participants
n=107 Participants
|
91 participants
n=206 Participants
|
|
Final diagnosis
Status epilepticus
|
404 participants
n=99 Participants
|
399 participants
n=107 Participants
|
803 participants
n=206 Participants
|
|
Final diagnosis
Nonepileptic spell
|
31 participants
n=99 Participants
|
32 participants
n=107 Participants
|
63 participants
n=206 Participants
|
|
Final diagnosis
Undetermined
|
13 participants
n=99 Participants
|
14 participants
n=107 Participants
|
27 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Duration of prehospital care, outcome is determined upon arrival at the ED on the day of enrollment (average 20 minutes).The primary outcome was termination of seizures before arrival in the emergency department (ED) without the need for the paramedics to provide rescue therapy. Subjects did not reach the primary outcome if they were having seizures on arrival in the emergency department or if they received rescue medication before arrival. Termination of seizures on arrival was determined according to the clinical judgment of the attending emergency physician and was based on examination of the subjects, their clinical course, and results of any routine diagnostic testing.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With Termination of Seizures at ED Arrival With no Rescue Therapy Given
|
329 participants
|
282 participants
|
SECONDARY outcome
Timeframe: anytime before 30 minutes after ED arrivalEndotracheal intubation performed or attempted by EMS or within 30 minutes after ED arrival is abstracted from the ED record physician and nursing records. Endotracheal intubation includes placement of a definitive tracheal airway (oro-, naso-, cricothyroidotomy, or tracheostomy) for support of respirations or protection of airway. Non-definitive and/or non-tracheal airways (oral or nasal airways, laryngeal mask airways, or esophageal obturator airways) are not included if the patient is not subsequently intubated unless specifically deemed to have been used in lieu of tracheal intubation.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With Endotracheal Intubation Within 30 Min After ED Arrival
|
63 participants
|
64 participants
|
SECONDARY outcome
Timeframe: at ED disposition on day of enrollmentHospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects Hospitalized
|
258 participants
|
292 participants
|
SECONDARY outcome
Timeframe: at time of disposition on day of enrollmentHospital and ICU admission from the ED, and length of stay, is abstracted from the hospital admission record. ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects Admitted to an Intensive Care Unit (ICU)
|
128 participants
|
161 participants
|
SECONDARY outcome
Timeframe: within 12 hours after ED arrivalAcute seizure recurrence is defined as any further convulsive or electrographic seizures occurring in the first 12 hours of hospitalization, if they require additional antiepileptic medications, in subjects that had been determined not to be having seizures on ED arrival.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With Recurrent Seizure Within 12 Hours After ED Arrival
|
51 participants
|
47 participants
|
SECONDARY outcome
Timeframe: participants were followed for the duration of hospital stay, an average of 6 daysAcute hypotension is defined as a systolic blood pressure of \< 90 mmHg sustained for greater than 5 minutes and for which the patient was treated with a continuous IV infusion of a vasopressor.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With Hypotension
|
12 participants
|
13 participants
|
SECONDARY outcome
Timeframe: participants were followed for the duration of hospital stay, an average of 6 daysIM injection site complications are defined as any symptoms or signs of injury or reaction at the site of the study IM injection requiring treatment. This includes extensive hematoma requiring treatment (decompression, pressure dressings, or discontinuation of anticoagulant or antithrombotic medications). Treatment does not include imaging without other interventions. This definition also includes wound infection requiring antibiotic therapy, retained foreign bodies requiring exploration and removal, or other similar wound problems.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With IM Injection-site Complications
|
4 participants
|
2 participants
|
SECONDARY outcome
Timeframe: participants were followed for the duration of hospital stay, an average of 6 daysIV insertion site complications are defined as any symptoms or signs of injury or reaction at the site of the study IV placed by paramedics and used for study medication. This includes thrombosis, phlebitis, or skin infection requiring specific treatment including compresses, antibiotics, or wound care.
Outcome measures
| Measure |
IM Midazolam
n=448 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=445 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Number of Subjects With IV Injection-site Complications
|
0 participants
|
3 participants
|
SECONDARY outcome
Timeframe: participants were followed for the duration of hospital stay, an average of 6 daysPopulation: All participants with ICU length of stay data
Continuous days of initial ICU stay from time of admission
Outcome measures
| Measure |
IM Midazolam
n=123 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=155 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Length of Intensive Care Unit (ICU) Stay in Days
|
5.7 days
Standard Deviation 9.5
|
4.1 days
Standard Deviation 4.7
|
SECONDARY outcome
Timeframe: participants were followed for the duration of hospital stay, an average of 6 daysPopulation: All subjects with hospital length of stay data
Continuous acute care inpatient hospital days from day of admission until discharge
Outcome measures
| Measure |
IM Midazolam
n=251 Participants
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=285 Participants
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Length of Hospital Stay in Days
|
6.7 days
Standard Deviation 10.0
|
5.5 days
Standard Deviation 6.4
|
Adverse Events
IM Midazolam
IV Lorazepam
Serious adverse events
| Measure |
IM Midazolam
n=514 participants at risk
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=509 participants at risk
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Nervous system disorders
Depressed level of consciousness
|
9.5%
49/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
8.8%
45/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory depression
|
6.4%
33/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
10.0%
51/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Convulsion
|
6.4%
33/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
7.7%
39/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Mental status changes
|
1.8%
9/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
2.0%
10/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Infections and infestations
Sepsis/SIRS/organ failure
|
1.6%
8/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
1.6%
8/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Infections and infestations
Pneumonia/ Aspiration pneumonia
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
2.2%
11/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Myocardial infarction
|
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
1.4%
7/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Hypotension
|
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
1.4%
7/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.98%
5/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Alcohol/Drug withdrawal syndrome
|
0.97%
5/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.98%
5/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Cerebral hemorrhage
|
0.78%
4/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Renal and urinary disorders
Renal failure, acute
|
0.78%
4/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Ischemic stroke
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.59%
3/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Endocrine disorders
Hypoglycemia
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Blood and lymphatic system disorders
Anemia
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Bradycardia
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Cardiac arrest
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Vascular disorders
Deep vein thrombosis
|
0.39%
2/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Hypothermia
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Pyrexia
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.39%
2/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Apnea
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain mass
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Encephalopathy
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Vascular disorders
Pulmonary embolism
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Chest pain
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Delirium
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Hematoma
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Renal and urinary disorders
Hematuria
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Endocrine disorders
Hyperglycemic hyperosmolar nonketotic syndrome
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Subarachnoid hemorrhage
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Psychiatric disorders
Suicidal ideation
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Blood and lymphatic system disorders
Transfusion reaction
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Psychiatric disorders
Pseudoseizures
|
0.19%
1/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.00%
0/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Cardiogenic shock
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Musculoskeletal and connective tissue disorders
Fracture
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Cardiac disorders
Hypertension
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Post-extubation stridor/airway obstruction
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Psychiatric disorders
Psychosis
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Respiratory, thoracic and mediastinal disorders
Stridor
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Skin and subcutaneous tissue disorders
Toxic epidermal necrolysis
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Gastrointestinal disorders
Vomiting/Nausea
|
0.00%
0/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
0.20%
1/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
Other adverse events
| Measure |
IM Midazolam
n=514 participants at risk
Subjects in whom the study IM autoinjector contained active treatment with midazolam
|
IV Lorazepam
n=509 participants at risk
Subjects in whom the study IV infusion contained active treatment with lorazepam
|
|---|---|---|
|
Nervous system disorders
Convulsion
|
8.8%
45/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
7.5%
38/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Nervous system disorders
Mental status changes
|
3.9%
20/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
3.9%
20/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
Gastrointestinal disorders
Vomiting/Nausea
|
2.9%
15/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
4.5%
23/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
|
General disorders
Pyrexia
|
4.5%
23/514 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
2.8%
14/509 • Serious adverse events were collected through subject end of study (emergency department or hospital discharge).
Number of participants at risk includes every enrollment (including repeat enrollments in some subjects). This reflects the number of interventions given.
|
Additional Information
Robert Silbergleit MD, Principal Investigator
University of Michigan
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place